Obviousness

Obviousness Analysis of U.S. Patent 12,161,628 under 35 U.S.C. § 103

This analysis evaluates whether the claimed invention in U.S. Patent 12,161,628 would have been obvious to a person having ordinary skill in the art (PHOSITA) at the time the invention was made. The standard for obviousness is whether the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious to a PHOSITA.

A PHOSITA in this context would be a clinical pharmacologist or medical oncologist with experience in prostate cancer therapeutics, pharmacokinetics, and drug-drug interactions, particularly those involving the cytochrome P450 enzyme system.

Claim at Issue

The analysis focuses on independent Claim 1, which recites:

• Claim 1: A method of treating prostate cancer in a patient to whom rifampin is administered, comprising co-administering to the patient a daily dose of 240 mg enzalutamide.

The dependent claims (2-6) narrow the type of prostate cancer and are therefore rendered obvious if Claim 1 is obvious.

Proposed Combination of Prior Art

A strong case for obviousness can be made by combining the knowledge of enzalutamide's standard clinical use with the teachings of WO2017027660A1 (hereafter '660).

1. Primary Reference: General knowledge in the art regarding enzalutamide (marketed as XTANDI®). A PHOSITA would have known:

   • Enzalutamide is an androgen receptor inhibitor approved for treating prostate cancer.
   • The standard, FDA-approved daily dose of enzalutamide is 160 mg.
   • Enzalutamide is primarily metabolized by CYP2C8 and CYP3A4. Strong inducers of these enzymes are known to affect the plasma concentration of drugs they metabolize.

2. Secondary Reference: WO2017027660A1, which teaches a "Combination therapy with apalutamide."

Analysis of the Combination

The '660 reference does not anticipate the claims because it deals with apalutamide, not enzalutamide. However, its teachings provide a clear roadmap that would have led a PHOSITA to the invention of the '628 patent with a reasonable expectation of success.

1. Motivation to Combine

A PHOSITA would have been motivated to combine the general knowledge of enzalutamide with the teachings of '660 for several reasons:

• Same Drug Class, Same Problem: The '660 reference addresses the precise problem of a strong CYP3A4 inducer (rifampin) reducing the plasma concentration of a second-generation androgen receptor inhibitor (apalutamide). A PHOSITA would have immediately recognized that enzalutamide, being in the same therapeutic and structural class and metabolized by CYP3A4, would almost certainly face the same issue when co-administered with rifampin. The '660 reference explicitly identifies a known problem and presents a solution.

• Explicit Solution Taught: The '660 reference teaches that the solution to this drug-drug interaction is to increase the daily dose of the androgen receptor inhibitor to compensate for the decreased exposure. This provides a direct suggestion to a PHOSITA facing the same problem with enzalutamide.

2. Reasonable Expectation of Success and the Obviousness of the 240 mg Dose

The most critical element of the analysis is whether a PHOSITA would have arrived at the specific dose of 240 mg. The '660 reference provides a compelling reason to believe they would have.

• Analogous Dose Escalation: The '660 reference discloses that the standard dose for apalutamide is 240 mg/day. To counteract the effect of rifampin, it proposes increasing the dose to 360 mg/day. This represents a 50% increase in the standard dose (360 is 150% of 240).

• Direct Application to Enzalutamide: A PHOSITA, knowing the standard dose of enzalutamide is 160 mg/day, would be motivated by '660 to attempt a dose escalation of a similar magnitude to solve the same metabolic problem. Applying the same 50% dose increase taught for apalutamide directly to enzalutamide leads precisely to the claimed dose:

  • 160 mg (standard enzalutamide dose) * 1.50 = 240 mg

Therefore, the claimed 240 mg dose is not an arbitrary or unexpected finding. It is the exact figure one arrives at by applying the clear, quantitative teaching from a highly analogous prior art reference to the known standard of care for enzalutamide. The determination of this dose would not have required undue experimentation but would have been a predictable and logical starting point for dose adjustment based on the available art. The patent's own description of a potential dose range of "200-300 mg/day" further supports that this was a matter of routine optimization around a predictable value.

Conclusion

At the time of the invention, a person of ordinary skill in the art would have known the standard 160 mg dose of enzalutamide for treating prostate cancer. Upon reviewing WO2017027660A1, which addresses the identical problem of co-administration with rifampin for the closely related drug apalutamide, the PHOSITA would have been motivated to solve this problem for enzalutamide by increasing its dose. The prior art not only suggested a dose increase but provided a clear quantitative guide—a 50% increase. Applying this 50% increase to enzalutamide's standard 160 mg dose directly yields the claimed 240 mg dose.

For these reasons, Claim 1 of U.S. Patent 12,161,628 would have been obvious under 35 U.S.C. § 103. As dependent claims 2-6 merely specify the type of prostate cancer being treated, they would have been obvious for the same reasons.